Design of Experiments (DoE) Approach to Optimize the Sustained Release Microparticles of Gefitinib

(E-pub Ahead of Print)

Author(s): Govind Soni, Khushwant S. Yadav*, M. K. Gupta.

Journal Name: Current Drug Delivery

Become EABM
Become Reviewer


Gefitinib (GEF), the kinase inhibitor, is presently available as tablets to be taken orally in high doses of 250-500 mg per day due to its poor solubility. The solubility issues affect not only its onset of action but also the bioavailability. These drawbacks foresight the need to have an alternate dosage form, preferably a sustained release formulation. In the present study, microparticles were prepared by emulsion solvent evaporation using PLGA 50:50 (GEF-PLGA MP). A 32 factorial design was used to optimize the critical quality parameters to the set mean particle size in the range of 7.4±2.5

Keywords: Microparticles, Gefitinib, Sustained Release, Factorial design, Cytotoxicity

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1567201816666181227114109
Price: $95